

Henry Ford Health

Henry Ford Health Scholarly Commons

Dermatology Articles

Dermatology

12-1-2021

IL-36 α Enhances Host Defense against Pseudomonas aeruginosa Keratitis in C57BL/6 Mouse Corneas

Rao Me

Nan Gao

Yangyang Zhang

Patrick S Y Lee

Jie Wang

Henry Ford Health, jwang5@hfhs.org

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/dermatology_articles

Recommended Citation

Me R, Gao N, Zhang Y, Lee PSY, Wang J, Liu T, Standiford TJ, Mi QS, and Yu FX. IL-36 α Enhances Host Defense against Pseudomonas aeruginosa Keratitis in C57BL/6 Mouse Corneas. J Immunol 2021.

This Article is brought to you for free and open access by the Dermatology at Henry Ford Health Scholarly Commons. It has been accepted for inclusion in Dermatology Articles by an authorized administrator of Henry Ford Health Scholarly Commons.

Authors

Rao Me, Nan Gao, Yangyang Zhang, Patrick S Y Lee, Jie Wang, Tingting Liu, Theodore J. Standiford, Qing-Sheng Mi, and Fu-Shin X. Yu

IL-36 α Enhances Host Defense against *Pseudomonas aeruginosa* Keratitis in C57BL/6 Mouse Corneas

Rao Me,* Nan Gao,* Yangyang Zhang,* Patrick S. Y. Lee,* Jie Wang,[†] Tingting Liu,[†] Theodore J. Standiford,[‡] Qing-Sheng Mi,[†] and Fu-Shin X. Yu*

The IL-36 cytokines are known to play various roles in mediating the immune response to infection in a tissue- and pathogen-dependent manner. The present study seeks to investigate the role of IL-36R signaling in C57BL/6 mouse corneas in response to *Pseudomonas aeruginosa* infection. IL-36 $\alpha^{-/-}$, IL-36 $\gamma^{-/-}$, and IL-36R $^{-/-}$ mice had significantly more severe keratitis than wild-type mice. At six hours postinfection, IL-36 α pretreatment augmented *P. aeruginosa*-induced expression of IL-1Ra, IL-36 γ , LCN2, and S100A8/A9. At one day postinfection, exogenous IL-36 α suppressed, whereas IL-36 α deficiency promoted, the expression of IL-1 β . At three days postinfection, exogenous IL-36 α suppressed Th1 but promoted Th2 immune response. IL-36 α stimulated the infiltration of IL-22-expressing immune cells, and IL-22 neutralization resulted in more severe keratitis. IL-36 α alone stimulated dendritic cell infiltration in B6 mouse corneas. Taken together, our study suggests that IL-36R signaling plays a protective role in the pathogenesis of *P. aeruginosa* keratitis by promoting the innate immune defense, Th2, and/or Th22/IL-22 immune responses. Exogenous IL-36 α might be a potential therapy for improving the outcome of *P. aeruginosa* keratitis. *The Journal of Immunology*, 2021, 207: 2868–2877.

Microbial keratitis is a predominant cause of irreversible visual loss around the world (1). Among all the pathogens in microbial keratitis, *Pseudomonas aeruginosa* is the most aggressive and frequently isolated organism, especially in extended contact lens wearers (2). Corneal hypoxia, microtrauma, decreased tear production, and increased corneal temperature caused by the contact lens allows pathogens to easily adhere to the ocular surface (3, 4). *P. aeruginosa* keratitis is characterized by its rapid onset and progression, often presenting with strong inflammation and ulceration. Severe complications include anterior chamber hypopyon, descemetocoele formation, corneal scarring, and perforation (5).

Severe keratitis caused by *P. aeruginosa* results from both a high virulence of the pathogen and the extreme inflammatory response of the host (6). Various bacterial exotoxins and enzymes help *P. aeruginosa* digest and degrade the corneal matrix (7). In our experimental model, it takes ~18–24 hours for *P. aeruginosa* to cross the corneal epithelial basement membrane and reach the stroma (8). Hence, early recognition and enhanced host defense is essential to suppress bacterial invasion. The innate immunity also has profound effects on adaptive immunity, leading to different responses of the tissues to infection in a tissue- and pathogen-dependent manner. The adaptive immunity response can be activated by APCs (dendritic cells [DCs] and macrophages), residential immune

cells in avascular, naive corneas, that activate Th1, Th2, Th17, and/or Th22 immune responses (9). Conversely, an extensive immune response can also be destructive to the host tissue (10, 11). In the cornea, the Th2 immune response plays a protective role, whereas Th1 and Th17 are detrimental to *P. aeruginosa* keratitis (12, 13).

IL-36 cytokines are the newest members of the IL-1 superfamily and have been shown to play a role in tissue homeostasis and inflammation (14, 15). The IL-36 family consists of three agonists: IL-36 α , IL-36 β , and IL-36 γ . All three share a common heterodimeric receptor, IL-36R (16). Binding of IL-36 to IL-36R recruits the accessory protein IL-1RAcP, leading to the activation of the NF- κ b and MAPK pathways, and initiates downstream gene transcription (17). IL-36/36R signaling is activated in bacterial, viral, and *Mycobacterium pneumonia*, resulting in the elevation of antimicrobial activity (18–20). As a potent immune stimulator, IL-36 signaling has been shown to augment intestinal and skin inflammation (21, 22). Like IL-1 β , IL-36 cytokines also have a natural antagonist to their receptor, IL-36Ra. IL-36Ra and IL-38 bind IL-36R without recruiting the secondary receptor IL-1RAcP, thus interfering with IL36 signaling (23). Importantly, IL-38 was found to attenuate sepsis by decreasing inflammation and increasing bacterial clearance, suggesting that modulation of IL-36/IL-36R activity might be used to control or treat bacterial infection (24). In mouse models of tissue

*Department of Ophthalmology, Visual and Anatomical Sciences, Wayne State University School of Medicine, Detroit, MI; [†]Center for Cutaneous Biology and Immunology, Department of Dermatology and Immunology Program, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, MI; and [‡]Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI

ORCID: 0000-0003-3276-5211 (Y.Z.); 0000-0002-7203-9831 (P.S.Y.L.); 0000-0001-9732-1975 (J.W.); 0000-0002-8517-2738 (F.-S.X.Y.).

Received for publication November 2, 2020. Accepted for publication September 21, 2021.

This work was supported by the National Institutes of Health, National Eye Institute (NEI) (R01EY10869 and EY17960 to F.-S.X.Y.), (EY025923 to P.S.Y.L.), p30 EY004068 (NEI Core to Wayne State University), and Research to Prevent Blindness (to Kresge Eye Institute).

Author contributions: R.M. performed laboratory testing, sample collection/analysis, and edited and checked accuracy of the manuscript. N.G., P.S.Y.L., Y.Z., J.W., and T.L. performed laboratory testing and data analysis. T.J.S. and Q.-S.M. participated in experimental design. T.J.S. provided transgenic mice. F.-S.X.Y. was responsible for study design and recruitment, contributed to sample collection and data analysis, and reviewed and edited the manuscript.

Address correspondence and reprint requests to Fu-Shin X. Yu, Kresge Eye Institute, Wayne State University School of Medicine, 4717 St. Antoine Boulevard, Detroit, MI 48201. E-mail address: fyu@wayne.edu

The online version of this article contains supplemental material.

Abbreviations used in this article: CEC, corneal epithelial cell; DC, dendritic cell; dpi, day postinfection; hpi, hour postinfection; KO, knockout; MPO, myeloperoxidase; qPCR, quantitative PCR; mm, recombinant mouse; WT, wild-type.

Copyright © 2021 by The American Association of Immunologists, Inc. 0022-1767/21/\$37.50

infection, IL-36 agonists exhibited both beneficial and detrimental roles in a tissue- and pathogen-specific manner (18, 20, 25). Using small interfering RNA silencing, we recently showed that IL-36Ra and IL-1Ra played opposing roles in the innate immune response to *P. aeruginosa* infection, suggesting the potential antagonization of the IL-36/IL36R axis on the IL-1/IL-1R pathway (26). Conventionally, IL-36 γ was believed to be the main agonist of IL-36R in the mucosal epithelium (27). The knowledge of the role of IL-36 α in corneal or mucosal immunity is limited.

In this study, we defined the role of IL-36 α in mediating host defense following corneal *P. aeruginosa* infection. Using a murine model of *P. aeruginosa* keratitis, we showed an increase in IL-36 α expression in response to *P. aeruginosa* infection. IL-36 α protected the cornea by stimulating antimicrobial peptide production, promoting tissue healing by upregulating IL-22 and modulating immune cell infiltration.

Materials and Methods

Animals

Specific pathogen-free, age- and sex-matched C57BL/6 wild-type (WT) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). IL-36R^{-/-} mice on the C57BL/6 genetic background were provided by Amgen (Thousand Oaks, CA) (28). IL-36 α ^{-/-} and IL-36 γ ^{-/-} mice bred on a C57BL/6 background were established at the University of Michigan (29). All animal procedures were performed in compliance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Visual Research and were approved by the Institutional Animal Care and Use Committee of Wayne State University.

Mouse model of *P. aeruginosa* keratitis

Mice were anesthetized with an i.p. injection of ketamine (90 mg/kg) and xylazine (10 mg/kg) before surgical procedures. Mouse corneas were scratched gently with a sterile 26-gauge needle to create three 1-mm incisions to break the epithelial barrier and were inoculated with 1.0×10^4 CFU of ATCC 19660 in 5 μ l of PBS.

Administration of neutralizing Ab or recombinant protein

To apply neutralizing Abs or recombinant proteins, mice were subconjunctivally injected with recombinant mouse (rm) IL-36 α (100 ng/5 μ l; R&D Systems, Minneapolis, MN), anti-IL-22 Ab (400 ng/5 μ l; R&D Systems, Minneapolis, MN), or 0.1% BSA control 4 h before inoculation with *P. aeruginosa*.

Isolation of mouse corneal epithelial cells

Mice were euthanized by cervical dislocation. Under the microscope, mouse corneal epithelial cells (CECs) were surgically scraped off from the basement membrane. Cells were collected onto the razor blade. Liquid nitrogen was used to snap freeze the collected cells on the blade, then the frozen cells were immediately scraped off and transferred into precooled 1.5-ml Eppendorf tubes placed on dry ice. Cells were processed immediately for RNA isolation or protein extraction or were stored at -80°C for later use.

Clinical examination, quantification of *P. aeruginosa* CFU, and determination of myeloperoxidase units

Corneas were photographed at 1 d or 3 d postinfection (dpi) for the assessment of infection severity. Clinical scores were assigned to the infected corneas in a blinded fashion, according to a previously reported scale (30). Whole corneas were excised and placed in 200 μ l of sterile PBS. Tissue was homogenized with a TissueLyser II (QIAGEN, Valencia, CA). The homogenates were divided into two parts. The first fraction (50 μ l) was subjected to serial log dilutions for the assessment of viable bacterial numbers. The remaining homogenates were further lysed for myeloperoxidase (MPO) measurement. MPO units were determined according to a previously reported method (31). One MPO unit corresponds to 2.0×10^5 PMNs.

Semiquantitative and quantitative PCR

Total RNA was extracted with an RNeasy Mini Kit (QIAGEN) following the manufacturer's instructions. For semiquantitative PCR, cDNA was amplified with TaqMan technology (Promega, Madison, WI). PCR products were subjected to electrophoresis on 2% agarose gels containing ethidium bromide. For quantitative PCR (qPCR), cDNA was amplified using a StepOnePlus

Real-Time PCR system (Applied Biosystems, University Park, IL) with SYBR Green PCR Master Mix (Applied Biosystems). Data were analyzed by using the $\Delta\Delta$ cycle threshold method with β -actin as the internal control. The primers used in this study were listed in Table 1.

Western blot and ELISA

Mouse corneal samples were lysed with RIPA buffer. The lysates were centrifuged to obtain supernatant. Protein concentration was determined by bicinchoninic acid assay. For Western blot analysis, the protein samples were separated by SDS-PAGE and electrically transferred onto nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA). The membranes were blocked with 5% milk and subsequently incubated with primary and secondary Abs. Signals were visualized using SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific, Pittsburgh, PA). β -actin was used as the loading control. Quantification of protein levels was based on the densitometry of blots by using the software Carestream MI SE (Informer Technologies, Rochester, NY). The Abs used included anti-IL-36 α , anti-LCN-2 (R&D Systems), and anti- β -actin (Sigma-Aldrich). ELISA (S100A8/9, IL-22; R&D Systems) were performed following manufacturer's protocols.

Immunohistochemistry

At the indicated time points, the corneas were enucleated and separated into epithelium and stroma with EDTA; the whole corneas as well as separated epithelial sheet were embedded in Tissue-Tek OCT compound and frozen in liquid nitrogen. Six-micrometer-thick sections were cut and mounted to poly-L-lysine-coated glass slides, fixed in 4% paraformaldehyde, and blocked with PBS containing 2% BSA for 1 h at room temperature. Sections were then incubated with the following primary Abs: anti-NIMP-R14 (1:50; BD Biosciences), anti-F4/80 (1:50; BD Biosciences), anti-IL-22 (1:200; R&D Systems), and anti-IL-36 α (1:50; Abcam), followed by the secondary Ab FITC-conjugated IgG (1:100; Jackson ImmunoResearch Laboratories). Slides were mounted with VECTASHIELD (Vector Laboratories, Burlingame, CA) mounting media containing DAPI. Controls were similarly treated with corresponding IgG from the same animal as the primary Ab.

Flow cytometry analysis

Whole corneas and cervical lymph nodes were digested in 20 μ l of Liberase TL (2.5 mg/ml; Sigma-Aldrich), followed by incubation at 37°C for 45 min. Cell suspensions were passed through a 70- μ m filter. Viable cells were then counted using trypan blue dye exclusion. Cells were incubated at 4°C in PBS containing 2% FBS and Fc block. Intracellular staining was performed using a Foxp3 Fixation/Permeabilization Kit. The cells were labeled with conjugated CD45 (A20), CD4 (GK1.5), T-bet (eBio17B7), GATA3 (TWAJ), Ly-6G (RB6-BC5), F4/80(BM8), IL-36 α , and FITC-conjugated goat anti-rabbit Ab (eBioscience, Thermo Fisher Scientific, and Abcam). All samples were washed and reconstituted in PBS. Flow cytometry was performed with a FACS system (BD FACSCelesta and BD Accuri C6), and the data were analyzed using FlowJo software.

Statistical analysis

Data were presented as means \pm SD. Statistical differences among three or more groups were identified using one-way ANOVA, followed by a Bonferroni posttest to determine statistically significant differences. Analysis of clinical scores was performed by a nonparametric Mann-Whitney *U* test. Differences were considered statistically significant at $p < 0.05$.

Results

IL-36/IL-36R signaling plays a critical role in B6 mouse corneal immune defense against *P. aeruginosa* keratitis

Our previous study showed that the IL-36/IL-36R signaling opposes the role of IL-1 β /IL-1R in mediating corneal immune defense against *P. aeruginosa* infection (26). Our preliminary studies revealed that among the three IL-36R agonists, IL-36 α and $-\gamma$ but not $-\beta$ were upregulated in response to *P. aeruginosa* infection in B6 mouse corneas. To further elucidate the role of IL-36R signaling in the pathogenesis of *P. aeruginosa* keratitis, we used IL-36 α , IL-36 γ , and IL-36R knockout (KO) mice with WT B6 mice as the controls. These mice were inoculated with 1×10^4 CFU *P. aeruginosa* in scratch-wounded corneas (Fig. 1). The pathology of *P. aeruginosa* keratitis was analyzed using clinical scoring, bacterial plate counting, and MPO determination. The WT mice had mild and moderate




FIGURE 1. IL-36 signaling pathway protects B6 mouse corneas from *P. aeruginosa* infection. WT, IL-36 $\alpha^{-/-}$, IL-36 $\gamma^{-/-}$, and IL-36R $^{-/-}$ mouse corneas were gently scratched with a needle to create three 1-mm epithelium incisions and inoculated with 1.0×10^4 CFU *P. aeruginosa*. (A and B) Eyes were photographed (original magnification $\times 10$) and clinically scored from 1 to 3 dpi. The 1–12 scale clinical scores were graded by an independent blinded observer. All mice were euthanized at 3 dpi. The corneas were excised and subjected to (C) bacterial plate counting presented in log scale and (D) MPO determination. The data in (B)–(D) were presented as median of clinical score (median \pm interquartile range) and average of CFU or MPO units per cornea (mean \pm SD) in dot plots. The results were representative of three independent experiments. The *p* values were analyzed with one-way ANOVA, followed by a Bonferroni test. *n* = 5. **p* < 0.05, ***p* < 0.01, ****p* < 0.001.

keratitis at 1 and 3 dpi, respectively. Deficiency of IL-36 α and IL-36 γ increased the severity of *P. aeruginosa* keratitis, including higher opacification, significantly elevated clinical scores (9.0 ± 0 versus 10.2 ± 0.4 versus 11.2 ± 0.4), markedly increased bacterial burden (3.52×10^5 versus 5.68×10^6 versus 1.10×10^7 CFU), and patently augmented MPO activity (93.92 versus 141.12 versus 173.69 U), compared with WT mice. IL-36 $\gamma^{-/-}$ mice had more severe keratitis than IL-36 $\alpha^{-/-}$ mice, whereas IL-36R $^{-/-}$ mice had the most severe keratitis, with cornea melting as early as 3 dpi, suggesting a cumulative and nonoverlapping role of IL-36 α and IL-36 γ in the immune response to *P. aeruginosa* keratitis.

P. aeruginosa infection increases IL-36 α expression in B6 mouse cornea

Our previous study revealed a protective role of IL-36 γ in *P. aeruginosa* keratitis (26). Hence, we focused on the role of IL-36 α and investigated its expression in B6 mouse corneas in response to *P. aeruginosa* infection (Fig. 2). The levels of IL-36 mRNA were increased 8.12-fold in mouse corneas starting from six hours postinfection (hpi) and remaining high up to 18 hpi (16.82-fold) compared with the naive, control corneas (Fig. 2A). At the protein level, Western blot analysis showed IL-36 α expression in the scraped epithelial cells (Fig. 2B) and an increase in IL-36 α protein in the whole corneas starting at 6 hpi, a peak at 9 hpi, and remaining highly elevated up to 18 hpi (Fig. 2C). Immunohistochemistry revealed the corneal epithelium and numerous infiltrating cells are IL-36 α^+ at 1 dpi (Fig. 2D). The epithelium expression of IL-36 α at 1 dpi was further confirmed by separating epithelial sheet with the stroma, followed by Western blotting (Supplemental Fig. 2). Flow cytometry further showed both neutrophils and macrophages produce IL-36 α at 1 dpi (Fig. 2E). Taken together, Figure 2 reveals that both residential

epithelial cells and infiltrated immune cells are the sources of IL-36 α in *P. aeruginosa*-infected corneas at 1 dpi.

IL-36 α plays a protective role in *P. aeruginosa* keratitis in B6 mice

Having identified the increased expression of IL-36 α during *P. aeruginosa* infection in B6 mouse corneas, we next investigated the role of IL-36 α in *P. aeruginosa* keratitis using two complementary approaches: application of rIL-36 α prior to *P. aeruginosa* inoculation and using IL-36 α KO mice (Fig. 3). Mouse recombinant protein was subconjunctivally injected 4 h before *P. aeruginosa* inoculation. At 1 dpi and 3 dpi, rIL-36 α treatment resulted in a significant decrease in the severity of *P. aeruginosa* keratitis, including greatly reduced clinical scores (4.2 ± 0.5 versus 2.0 ± 0.0 ; 9.2 ± 0.5 versus 6.4 ± 0.9), significantly dampened bacterial burden (5.41×10^4 versus 2.33×10^3 CFU; 2.57×10^6 versus 2.43×10^5 CFU), and decreased MPO activity (13.75 versus 3.30 U; 104.42 versus 44.25 U), compared with the control-infected eyes. IL-36 α deficiency had opposing effects on *P. aeruginosa* keratitis outcome. To rule out direct effects of IL-36 α on *P. aeruginosa*, 100 ng of rIL-36 α in 1 ml with live bacteria exhibited no effects on *P. aeruginosa* survival and growth (Supplemental Fig. 1).

IL-36 α decreases neutrophil and macrophage infiltration in *P. aeruginosa*-infected corneas

Having demonstrated the protective effect of IL-36 α in *P. aeruginosa* keratitis, we next assessed its effect on the infiltration of innate immune cells in *P. aeruginosa*-infected corneas (Fig. 4). Although no neutrophil or macrophage staining was detected in the naive corneas, numerous NIMPR-14- (neutrophil marker) and F4/80- (macrophage marker) positive cells were observed in *P. aeruginosa*-infected corneal stroma at 1 dpi. IL-36 α treatment decreased the number of infiltrating neutrophils and macrophages compared with control-infected




FIGURE 2. *P. aeruginosa* infection increases IL-36 α expression in B6 mouse cornea. Mouse corneas were gently scratched with a needle to create three 1-mm epithelium incisions and inoculated with 1.0×10^4 CFU *P. aeruginosa* at 0 h. **(A)** Whole corneas were collected at 3 hpi, 6 hpi, 9 hpi, and 18 hpi for qPCR. The *p* values were analyzed with one-way ANOVA. *n* = 5. ****p* < 0.001. **(B)** Mouse CECs were collected at 6 hpi for Western blot analysis of IL-36 α . β -actin serves as loading control. **(C)** Cornea samples representing five time points were also collected for Western blot analysis of IL-36 α , with β -actin as loading control. Three samples of each time point were used in qPCR, and two samples were used in Western blot. **(D)** Corneas at 1 dpi were excised and processed for immunohistochemistry analysis. The 6- μ m cryostat sections were stained with anti-IL-36 α (red) and DAPI (blue) for nuclei. **(E)** Flow cytometric analyses of IL-36 α , CD45, Ly-6G, F4/80-positive immune cells in 1-dpi infected corneas. Six corneas were pooled for each sample. IL-36 α , CD45⁺Ly-6G⁺, CD45⁺F4/80⁺ cells are shown in the flow cytometric plots. The results were representative of three independent experiments. E, epithelium; S, stroma.

corneas (Fig. 4A). Quantification of neutrophil and macrophage infiltration was evaluated with flow cytometry (Fig. 4B, 4C). IL-36 α treatment significantly reduced the numbers of neutrophil and macrophage cell infiltration compared with the control group, which is consistent with immunohistochemistry findings.

Exogenous IL-36 α alters gene expression in response to *P. aeruginosa* infection in B6 mouse corneas

To explore the underlying mechanism of how IL-36 α influences the outcome of *P. aeruginosa* keratitis, we used qPCR to assess the effects of IL-36 α on the expression of several innate immune genes that we previously showed to be involved in corneal innate defense (Fig. 5) (Table I). At 6 hpi, rmIL-36 α treatment increased infection-induced expression of factors promoting innate defense, such as IL-1Ra (15.00- versus 50.64-fold) and IL-36 γ (4.04- versus 6.75-fold) and dampened the expression of factors suppressing corneal defense, such as IL-24 (319.80- versus 41.71-fold) in B6 mouse CECs (26, 32, 33). Notably, the expression of antimicrobial genes S100A8 (22.73- versus 322.50-fold), S100A9 (3.90- versus 13.34-fold), and LCN2 (6.99- versus 19.29-fold), were also greatly enhanced by rmIL-36 α at 6 hpi. rmIL-36 α exhibited no effects on IL-1 β (3.00- versus 3.54-fold) expression, and the levels of IL-22 (1.08- versus 1.07-fold) did not change in B6 mouse corneas at 6 hpi (Fig. 5A).

The expression of the aforementioned genes was also assessed in 1-dpi corneas. *P. aeruginosa* infection-induced levels of IL-1 β (811.58- versus 76.42-fold), IL-1Ra (1381.48- versus 214.85-fold), IL-24 (64.83- versus 4.03-fold), and immune cells IL-22 (2.24-




FIGURE 3. IL-36 α plays a protective role in *P. aeruginosa* keratitis in B6 mice. At 4 h before *P. aeruginosa* inoculation, WT mice were subconjunctivally injected with rmIL-36 α (100 ng/5 μ l), or 0.1% BSA as control. IL-36 $\alpha^{-/-}$ mice were subconjunctivally injected with 0.1% BSA. At 0 h, the corneas were gently scratched with a needle to create three 1-mm epithelium incisions and inoculated with 1.0×10^4 CFU *P. aeruginosa*. **(A and E)** Mouse corneas were monitored and photographed at 1 and 3 dpi, **(B and F)** and clinical scores were assigned as described in Figure 1. The corneas were excised and subjected to **(C and G)** bacterial plate counting (the results were presented at log scale) and **(D and H)** MPO unit determination. The data in **(B)–(D)** and **(F)–(H)** were presented as a median of clinical score (median \pm interquartile range) and average of CFU or MPO units per cornea (mean \pm SD). The results were representative of three independent experiments. The *p* values were generated by one-way ANOVA, followed by a Bonferroni test. *n* = 5. **p* < 0.05, ***p* < 0.01, ****p* < 0.001.

versus 1.35-fold), LCN-2 (83.87- versus 18.02-fold), and S100A8 (637.45- versus 277.65-fold) were all decreased in rmIL-36 α -treated corneas, consistent with the minimal inflammation in that group. In contrast, IL-36 α deficiency augmented the expression of IL-1 β (811.58- versus 1577.10-fold), IL-1Ra (1381.48- versus 2126.75-fold), IL-22 (2.24- versus 3.61-fold), LCN-2 (83.87- versus 155.56-fold), S100A8 (637.45- versus 2498.96-fold), and S100A9 (100.02- versus 217.20-fold). The elevation may be due to the severe inflammation in IL-36 $\alpha^{-/-}$ mouse corneas (Fig. 5B).

At the protein level, infection-induced expression of calprotectin (dimer of S100A8/9) and LCN2 were augmented by the addition of rmIL-36 α and dampened in IL-36 $\alpha^{-/-}$ corneal epithelia at 6 hpi (Fig. 5C, 5D).

IL-36 α promotes Th2 immune response in *P. aeruginosa*-infected B6 mouse corneas

At 1 dpi, corneal defense against *P. aeruginosa* infection is primarily carried out by the innate immune defense apparatus, whereas




FIGURE 4. IL-36 α ameliorates *P. aeruginosa*-induced inflammation in the B6 mouse corneas. WT mouse corneas were treated with rmIL-36 α or 0.1% BSA and inoculated with *P. aeruginosa* as in Figure 3. Naive corneas were used as negative control. The corneas were collected at 1 dpi (A) The corneas were processed for immunohistochemistry analysis. 6- μ m cryostat sections were stained with NIMP-R14 Ab for neutrophils or F4/80 Ab for macrophages. The images of neutrophils (green) and macrophages (green) were merged with DAPI (blue nuclei) staining. Three independent experiments were performed; one representative image for each condition is presented. (B) The corneas were processed for flow cytometry analysis and stained with CD45, Ly-6G, and F4/80 Abs. Six corneas were pooled for each sample. (C) Three samples of each groups were used for neutrophil and macrophage cell percentage statistical analysis (mean \pm SD). Three independent experiments were performed; one representative image for each condition is presented. The *p* values were generated by one-way ANOVA. **p* < 0.05, ***p* < 0.01, ****p* < 0.001. E, epithelium; S, stroma.

adaptive immunity is expected to be initiated, activated, and ultimately participate in the corneal defense at 3 dpi. To determine how IL-36R signaling affects adaptive immune responses, we assessed the expression of two selected cytokines each from Th1 and Th2 pathways (Fig. 6) in 3-dpi corneas. rmIL-36 α suppressed Th1 (IFN- γ , 5.65- versus 1.89-fold and IL-12, 3.54- versus 1.96-fold) and enhanced Th2 cytokine (IL-4, 2.47- versus 3.85-fold and IL-5, 1.06- versus 3.95-fold) expression, whereas IL-36R depletion exhibited no apparent effects on the mRNA expression of these genes.

Flow cytometry revealed that CD45- and CD4-positive T cells were abundant in mouse cervical lymph nodes but barely detectable in the corneas. Further analysis revealed that in 3-dpi mouse cervical lymph nodes, the percentage of Th2 cells was significantly higher in rmIL-36-treated mice and lower in IL-36R^{-/-} mice (Fig. 6B, 6C). The gating strategy was shown in Supplemental Fig. 4. Immunohistochemistry showed that some IL-36 α ⁺ cells were also GATA3 positive, suggesting that Th2 cell may also produce IL-36 α in the cornea at 3 dpi (Supplemental Fig. 3).

*IL-36 α induces the infiltration of IL-22-expressing cells, and IL-22 neutralization worsens *P. aeruginosa* keratitis*

We recently reported that neutralization of IL-23 regulated IL-17Ra signaling and improved the outcome of *P. aeruginosa* keratitis, suggesting a detrimental role of the IL-23–IL-17 axis in *P. aeruginosa* keratitis (12). IL-23 is also known to induce IL-22 expression, and the IL-23–IL-22 axis was shown to regulate intestinal microbial homeostasis to protect from diet-induced atherosclerosis (34). To that end, we investigated the relationship of IL-22 expression with IL-36 signaling and the role of IL-22 signaling in immune defense against *P. aeruginosa* keratitis (Fig. 7). Immunostaining showed that a single dose of rmIL-36 α injection to eyes without *P. aeruginosa* infection resulted in the recruitment of IL-22⁺ cells that migrated from the limbus toward the central cornea 1 d after IL-36 α treatment, with more staining near the limbus compared with the central cornea. No IL-22 staining was observed in the control BSA-injected corneas. The stromal IL-22-positive cells were costained with macrophage marker F4/80 (Fig. 7B).




FIGURE 5. IL-36 α alters gene expression in B6 mouse corneas in response to *P. aeruginosa* infection. WT, IL-36 $\alpha^{-/-}$ mouse corneas were treated with rmIL-36 α or 0.1% BSA and inoculated with *P. aeruginosa* as in Figure 3. (A) CECs were collected at 6 hpi, and (B) whole cornea samples were collected at 1 dpi (immune cell infiltration occurs after 6 hpi) and analyzed by real-time PCR. The results were presented as a relative increase (fold) to those of naive corneas, which were set as a value of 1. CECs were collected at 6 hpi for (C) ELISA analysis of S100A8/9 dimer, (D) Western blot analysis of LCN2. Data were representative of three independent experiments with three corneas per group (mean \pm SD). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, one-way ANOVA.

The function of IL-22 in *P. aeruginosa* keratitis was also evaluated using subconjunctival injection of IL-22–neutralizing Ab. Compared with the control corneas injected with IgG, IL-22 neutralization resulted in a marked increase in the severity of *P. aeruginosa* keratitis (Fig. 7B–D) at 3 dpi. There were higher clinical scores (8.8 ± 0.4 versus 10.4 ± 0.8), bacterial burden (6.70×10^5 ; 2.33×10^7 CFU), and MPO activity (77.17 versus 138.41 U) in anti-IL-22–treated corneas compared with nonspecific IgG-treated corneas.

Exogenous IL-36 α induces DC infiltration in B6 mouse corneas

The aforementioned results indicate that IL-36R signaling induced infiltration of IL-22–expressing cells (Th17 and Th22 cells). Because DCs are known to be more sensitive to IL-36 than IL-1 β in inducing the production of proinflammatory cytokines IL-12, IL-1 β , IL-6, and IL-23 (35), we next assessed whether IL-36 α induces DC infiltration in B6 mouse corneas (Fig. 8). At 1 dpi, IL-36 α stimulated the migration of numerous CD11c-positive cells from the limbal region toward the central cornea. Most of the recruited CD11c-

positive cells were round-shaped rather than dendriform DCs. There were only a few dendriform DCs near the limbal region in control-infected corneas (Fig. 8A). Statistical analysis showed that there were more CD11c-positive cells in rmIL-36 α –treated corneas (Fig. 8B).

Discussion

In this study, we investigated the role of IL-36 α and IL-36R signaling in *P. aeruginosa* keratitis in B6 mice. We demonstrated that IL-36R signaling is required for the proper response of B6 mice to *P. aeruginosa* infection and that IL-36 α and IL-36 γ each contribute to the protective effects of IL-36R signaling. We demonstrated that *P. aeruginosa* infection induces the upregulation of IL-36 α in the cornea and, in addition to the epithelia, certain infiltrated cells also express IL-36 α . Functionally, exogenous IL-36 α decreases the severity of *P. aeruginosa* keratitis, promotes bacterial clearance, and ameliorates infection-induced inflammation, whereas IL-36 α , IL-36 γ , or IL-36R deficiency impairs bacterial clearance and exacerbates *P. aeruginosa*–induced inflammation.

Table I. Primer sequences used for PCR

Primers	Forward (5'→3')	Reverse (5'→3')
mβ-actin	GACGGCCAGGTCATCACTATTG	AGGAAGGCTGGAAAAGAGCC
mIL-36α	CCAAGAAGTGGGGAAATCT	GGAGGGCTCAGCTTTCTTTT
mIL-36γ	CCCATGCAAGTACCCAGAT	GGGAAAGCCACTGATTCAAA
mIL-1β	TGCCACCTTTTGACAGTGATG	AAGGTCCACGGGAAAGACAC
mIL-1Ra	GGGACCTACAGTCACCTAA	GGTCCTTGTAAGTACCCAGCA
mIL-22	CAGGAGGTGGTGCCTTTCTCT	TGGTCGTACCCTGATGT
mIL-23	AGAAGAAGAGGATGAAGAGAC	GGTGTGAGTTGGTCCAT
mIL-24	GCTTTCACCAAAGCGACTTC	GCCCAGTAAGGACAATTTCCA
mIL-17A	TTTAACCTCCCTTGGCGCAAAA	CTTCCCTCCGCATTGACAC
mIL-17F	GAGGATAACACTGTGAGAGTTGAC	GAGTTCATGGTGTCTCTTCC
mIL12	GGTCACACTGGACCAAAGGACTATG	ATTCTGCTGCCCTGCTTCCAAC
mIFN-γ	GTTACTGCCACGGCACAGTCATTG	ACCATCTTTTGCCAGTTCCTCCAG
mIL-4	TAGTTGTCATCCTGCTCTT	CCAGTACTACGAGTAATCCA
mIL-5	AAAGAGAAGTGTGGCGAGGAGAGAC	CCTTCCATTGCCACTCTGTACTCATC
mLCN2	CTGAATGGGTGGTACTGTG	GCTCTCTGGCAACAGGAAAG
mS100A8	TTCGTGACAATGCCCTCTGA	AGGGCATGGTATTTCTTGT
mS100A9	TGGGCTTACACTGCTCTTACC	GGTTATGCTGCGCTCCATCT

m, mouse.

Exogenous IL-36α also dampens the expression of proinflammatory cytokines/chemokines and stimulates anti-inflammatory and antimicrobial gene expression. We also found that IL-36α suppressed the mRNA expression of Th1 and promoted Th2 immune responses in *P. aeruginosa*-infected mouse corneas. Flow cytometry revealed that IL-36α promoted, whereas IL-36R deficiency suppressed, Th2 immune response in mouse cervical lymph nodes. Moreover, IL-36 induced IL-22 expression in mouse corneas, and neutralizing IL-22 exacerbated the severity of *P. aeruginosa* keratitis. IL-36α alone recruited DCs to B6

mouse corneas. Taken together, we conclude that IL-36R signaling mediates corneal immune defense against *P. aeruginosa* infection through its effects on both innate and adaptive immunity, by regulating inflammatory response, inducing antimicrobial effectors, and modulating Th2 response and/or Th1/Th2 balance in B6 mice.

Our studies show that IL36α mRNA was detected in the naive corneas, suggesting a basal level of expression. *P. aeruginosa* infection induces IL-36α upregulation in corneal epithelium as early as six hours postinfection. Compared with IL-1β, the expression of which can be detected as early as one hour postinfection and




FIGURE 6. IL-36 signaling regulates adaptive immune gene expression in B6 mouse corneas in response to *P. aeruginosa* infection. rmIL-36α or 0.1% BSA-treated WT mice, IL-36R^{-/-} mice were scratched and inoculated with *P. aeruginosa*. **(A)** At 3 dpi, whole cornea samples were collected and analyzed by real-time PCR. The results were presented as a relative increase (fold) to those of naive corneas, which were set as a value of 1. Three corneas per group (mean ± SD) were examined. **(B)** Six mouse corneas and two cervical lymph nodes were pooled for each sample for flow cytometric analysis. The samples were stained with CD45, CD4, T-bet, and GATA3 Ab. Th1 and Th2 cell percentage of mouse lymph nodes was shown in FACS plots. **(C)** Th1 and Th2 cell percentage out of the total CD4⁺ T cell population as well as total cell number were analyzed. Data were representative of three independent experiments with three samples per group. **p* < 0.05, ***p* < 0.01, ****p* < 0.001, one-way ANOVA. LN, lymph node.




FIGURE 7. IL-22 as a downstream cytokine of IL-36 α improves the outcome of *P. aeruginosa* keratitis. WT mice were subconjunctivally injected with rmIL-36 α or 0.1% BSA as control, given 4 h prior to *P. aeruginosa* inoculation. At 1 dpi, corneas were excised and processed for immunohistochemistry analysis. The 6 μ m cryostat sections were stained with (A) anti-IL-22 (green) and DAPI (blue) for nuclei (arrowheads represent the IL-22-positive cells) or with anti-IL-22 (red) and F4/80 (green) Abs (B) (arrowheads represent IL-22⁺ and F4/80⁺ cells). (C–E) Infected corneas were photographed and scored at 1 and 3 dpi and collected at 3 dpi for CFU and MPO determination. (C) The numbers within each eye micrograph are the clinical scores assigned and presented as median plus interquartile range. Data are representative of three independent experiments. Data in (D) and (E) were presented as an average of CFU or MPO units per cornea (mean \pm SD). $n = 5$. ** $p < 0.01$, by paired t test. E, epithelium; L, limbus; S, stroma.

increases with time after *P. aeruginosa* infection, the upregulation of IL-36 cytokines are at a relatively late stage, detectable in the cornea and more apparent in the corneal epithelia at six hours postinfection (26). Although IL-36 is mostly detected in corneal epithelium at six hours postinfection, it was observed in infiltrated cells, neutrophils, and macrophages, as well as epithelial cells, at one day postinfection. The relatively late upregulation of IL-36 α may be related to the fact that, unlike the IL-1 isoforms, IL-36 agonists have a basal expression in naive corneas. Alternatively, this may be related to the suggested function of the IL-36 family to counteract or antagonize the IL-1 cytokine family after IL-1R activation (26).

Emerging data suggests a significant role of IL-36 in mucosal tissues (36). IL-36 $\gamma^{-/-}$ mice have higher mortality and morbidity in *Streptococcus pneumoniae* and *Klebsiella pneumoniae* pulmonary infections, with insufficient type 1 cytokine production (20). However,




FIGURE 8. IL-36 α regulates DC infiltration in B6 mouse corneas. rmIL-36 α or 0.1% BSA was subconjunctivally injected into WT mouse corneas. (A) At 1 dpi, mouse corneas were collected for whole mount staining with CD11c (green) Ab. (B) The number of CD11c-positive cells was quantified and analyzed. Data were representative of three independent experiments with three corneas per group. *** $p < 0.001$, paired t test.

in the murine *Legionella pneumoniae* model, both IL-36 α and IL-36 γ were upregulated at mRNA and protein levels in infected lung, and only IL-36R^{-/-} (but not IL-36 $\alpha^{-/-}$ or IL-36 $\gamma^{-/-}$) mice exhibited increased mortality, suggesting that IL-36 α and IL-36 γ have overlapping functions (37). In humans, IL-36 α was shown to be highly expressed in the serum and in the salivary glands of primary Sjogren syndrome patients (38). Our data in the current study using IL-36 $\alpha^{-/-}$, IL-36 $\gamma^{-/-}$, and IL-36R^{-/-} mice revealed that all three KO mice have more severe keratitis than WT controls, and the severity of keratitis varies, with IL-36R^{-/-} greater than IL-36 $\gamma^{-/-}$ greater than IL-36 $\alpha^{-/-}$ in terms of decreasing severity. Hence, both IL-36 α and IL-36 γ contribute to IL-36R signaling-mediated anti-inflammatory and antimicrobial responses and to the host defense against *P. aeruginosa* keratitis in B6 mouse corneas. We conclude that IL-36 α and IL-36 γ each play a nonredundant role in mediating corneal immune protection in response to *P. aeruginosa* infection.

How does IL-36 α enhance host defense and protect the cornea from *P. aeruginosa* infection? Our data show that IL-36 α or IL-36R signaling is involved in the innate immunity against *P. aeruginosa* infection. The epithelium is the first barrier encountered and is the major site for innate immune defense at early stages of infection (39). We showed in this study that activation of IL-36R signaling improved *P. aeruginosa* keratitis outcomes, and decreased both bacterial load and MPO, indicative of neutrophil infiltration. Neutrophils, which are the first immune cells to respond to *P. aeruginosa* keratitis, promote bacterial clearance and the production of proinflammatory cytokines. As such, one would expect that MPO activity is elevated in IL-36 α -treated corneas and is attenuated in IL-36R^{-/-} corneas. Our results showed opposing effects. Our previous studies showed that in our model most bacteria were detected within the epithelium up to 24 hours after *P. aeruginosa* inoculation. In the current study, we observed that the expression of antimicrobial peptides LCN2 and calprotectin was augmented, whereas expression of factors

exacerbating keratitis, IL-24 and MMP13 (data not shown), were attenuated by IL-36 α treatment at six hours postinfection. As expected, IL-36R^{-/-} corneas have the opposite effects, providing a molecular mechanism for the protective effects of IL-36 signaling at early stages of infection. More importantly, we showed that at the protein level, IL-36 α significantly augments, whereas IL-36R KO downregulates the expression of calprotectin (S100A8/S100A9 dimer) and LCN-2 at six hours postinfection in CECs. Calprotectin can potently kill bacteria and fungi by chelating zinc and manganese (40, 41). LCN2 sequesters bacterial siderophores and interferes with their iron metabolism (42). LCN2 was shown to be required for pulmonary host defense against *Klebsiella*, an opportunistic extracellular pathogen, and the epithelium-produced LCN2 is important for resistance to dissemination of *K. pneumoniae* (43, 44). Hence, we propose that epithelium-produced LCN2, calprotectin, and potentially other AMPs, such as CXCL10 and CRAMP (45, 46), work together to eliminate invading *P. aeruginosa* within the epithelium at the early stages of infection (six hours postinfection), resulting in a decrease in the overall inflammatory response. At one day postinfection, the expressions of these factors appeared to be more likely associated with the severity of keratitis. Hence, the innate immune response at six hours postinfection, when the number of invading pathogens starts to increase in our model of *P. aeruginosa* keratitis, is a critical time point for determining the outcome of *P. aeruginosa* keratitis. Taken together, the epithelium-expressed IL-36 α enhances innate host defense by upregulating multiple antimicrobial genes and controls inflammation by inhibiting proinflammatory cytokines, promoting anti-inflammatory cytokine expression, and suppressing neutrophil and macrophage infiltration.

Our study also suggests a role of IL-36 α and IL-36R signaling in mediating the adaptive immune response to *P. aeruginosa* infection in B6 mouse corneas. Th1 and Th2 are well-characterized adaptive immune responses to pathogens (47). Th1 cells produce IFN- γ to promote cellular immune responses against intracellular microorganisms, whereas Th2 cells produce IL-4, IL-5, and IL-13 to promote humoral immune responses against parasites, extracellular bacteria, and allergens. Consistent with the protective role of IL-36R signaling, our data show that, at the mRNA levels, exogenous IL-36 α suppresses Th1 and promotes Th2 response in *P. aeruginosa*-infected corneas, whereas IL-36R exhibited opposing effects. Early studies have shown that *P. aeruginosa* infection results in CD4⁺ T cell infiltration in the cornea and becomes readily apparent as early as three days postinfection, with subsequent migration of activated CD4⁺ T cells by five days postinfection (10, 13, 48–50). To determine whether Th1 and/or Th2 cells play a role in keratitis, we performed flow cytometry analysis of infected corneas and local draining lymph nodes. Our data showed only a barely detectable population of CD4-positive T cells in the infected corneas at three days postinfection. In the cervical lymph nodes, the Th2 (GATA3-positive) cell percentage was significantly higher in the exogenous IL-36 α -treated group and lower in IL-36R^{-/-} lymph nodes compared with the control infection group. Hence, IL-36R signaling appears to promote Th2 immune responses, consistent with reports that Th2 is protective, whereas Th1 is detrimental for *P. aeruginosa* keratitis (13). In this case, IL-36 modulates the Th response by decreasing the Th1/Th2 ratio and thus protecting of the cornea from *P. aeruginosa* keratitis.

IL-22 is a cytokine in the IL-10 family that is expressed by cells of the innate and adaptive immune system, including Th17 as well as Th22 cells. IL-22 is known to promote host defense, epithelial barrier function, and tissue repair in mucosal surfaces (25, 51, 52). Our results show that at an early stage of corneal infection, six hours postinfection, there was no IL-22 induction, and at one day postinfection, its expression appeared to be correlated to the severity of *P. aeruginosa* keratitis, consistent with immune cells as the source of

IL-22. Indeed, we showed that rIL-36 α alone is sufficient to induce the infiltration of immune cells expressing IL-22 from the limbal region into the corneas assessed at 24 hours after application of the recombinant protein. Neutralization of IL-22 resulted in greatly increased severity of *P. aeruginosa* keratitis. We propose that IL-36/IL-36R signaling functions as an upstream inducer of Th22 immune response in the cornea, hence promoting bacterial clearance and tissue healing in response to *P. aeruginosa*-infected corneas. IL-22 is known to induce the production of AMPs, such as S100A8, S100A9, β -defensin 3 and Reg (51, 53, 54), and a recent study identified IL-36/IL-36R signaling as a central upstream driver of the IL-23/IL-22/AMP pathway during intestinal injury (25). Our study showed the infection-induced and IL-36 α -mediated IL-22 expression and potential involvement of Th22 cells in protecting corneas from *P. aeruginosa* keratitis.

In addition to IL-22-expressing immune cells, we also showed that IL-36 α alone stimulated the infiltration of DCs. Both myeloid and monocyte-derived DCs express IL-36R and respond to IL-36, whereas human T cells or neutrophils do not (55). Myeloid and monocyte-derived DCs may induce both Th1 and Th2 cytokines in naive allogeneic T lymphocytes (56). Our data suggests that IL-36 α stimulates DC infiltration and may be a contributing factor for DCs to drive Th2 immune responses in *P. aeruginosa*-infected corneas.

Taken together, our study demonstrates a vital role of IL-36/IL-36R in the corneal innate immunity against *P. aeruginosa* infection. IL-36 α enhances host defenses by upregulating AMPs and IL-22 and modulates immune cell gene expression and infiltration, suggesting a critical role of IL-36 in the interplay between CECs and immune cells. IL-36 α might be used as an adjunctive therapeutic reagent to antibiotics for treating *P. aeruginosa* and/or other forms of microbial keratitis.

Disclosures

The authors have no financial conflicts of interest.

References

- Al-Mujaini, A., N. Al-Kharusi, A. Thakral, and U. K. Wali. 2009. Bacterial keratitis: perspective on epidemiology, clinico-pathogenesis, diagnosis and treatment. *Sultan Qaboos Univ. Med. J.* 9: 184–195.
- Cheng, K. H., S. L. Leung, H. W. Hoekman, W. H. Beekhuis, P. G. Mulder, A. J. Geerards, and A. Kijlstra. 1999. Incidence of contact-lens-associated microbial keratitis and its related morbidity. *Lancet* 354: 181–185.
- Stapleton, F., and N. Carnit. 2012. Contact lens-related microbial keratitis: how have epidemiology and genetics helped us with pathogenesis and prophylaxis. *Eye (Lond.)* 26: 185–193.
- Slusher, M. M., Q. N. Myrvik, J. C. Lewis, and A. G. Gristina. 1987. Extended-wear lenses, biofilm, and bacterial adhesion. *Arch. Ophthalmol.* 105: 110–115.
- Guembel, H. O., and C. Ohrloff. 1997. Opportunistic infections of the eye in immunocompromised patients. *Ophthalmologica* 211(Suppl 1): 53–61.
- Janeway, C. A., Jr., and R. Medzhitov. 2002. Innate immune recognition. *Annu. Rev. Immunol.* 20: 197–216.
- Sadikot, R. T., T. S. Blackwell, J. W. Christman, and A. S. Prince. 2005. Pathogen-host interactions in *Pseudomonas aeruginosa* pneumonia. *Am. J. Respir. Crit. Care Med.* 171: 1209–1223.
- Hyndiuk, R. A. 1981. Experimental *Pseudomonas* keratitis. *Trans. Am. Ophthalmol. Soc.* 79: 541–624.
- Iwasaki, A., and R. Medzhitov. 2015. Control of adaptive immunity by the innate immune system. *Nat. Immunol.* 16: 343–353.
- Hazlett, L. D. 2004. Corneal response to *Pseudomonas aeruginosa* infection. *Prog. Retin. Eye Res.* 23: 1–30.
- Strieter, R. M., T. J. Standiford, G. B. Huffnagle, L. M. Colletti, N. W. Lukacs, and S. L. Kunkel. 1996. “The good, the bad, and the ugly.” The role of chemokines in models of human disease. *J. Immunol.* 156: 3583–3586.
- Me, R., N. Gao, C. Dai, and F. X. Yu. 2020. IL-17 promotes *Pseudomonas aeruginosa* keratitis in C57BL/6 mouse corneas. *J. Immunol.* 204: 169–179.
- Hazlett, L. D., S. McClellan, B. Kwon, and R. Barrett. 2000. Increased severity of *Pseudomonas aeruginosa* corneal infection in strains of mice designated as Th1 versus Th2 responsive. *Invest. Ophthalmol. Vis. Sci.* 41: 805–810.
- Garlanda, C., C. A. Dinarello, and A. Mantovani. 2013. The interleukin-1 family: back to the future. *Immunity* 39: 1003–1018.
- Walsh, P. T., and P. G. Fallon. 2018. The emergence of the IL-36 cytokine family as novel targets for inflammatory diseases. *Ann. N. Y. Acad. Sci.* 1417: 23–34.

16. Dinarello, C., W. Arend, J. Sims, D. Smith, H. Blumberg, L. O'Neill, R. Goldbach-Mansky, T. Pizarro, H. Hoffman, P. Bufler, et al. 2010. IL-1 family nomenclature. [Published erratum appears in 2011 Nat. Immunol. 12: 271.] *Nat. Immunol.* 11: 973.
17. Towne, J. E., K. E. Garka, B. R. Renshaw, G. D. Virca, and J. E. Sims. 2004. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. *J. Biol. Chem.* 279: 13677–13688.
18. Aoyagi, T., M. W. Newstead, X. Zeng, S. L. Kunkel, M. Kaku, and T. J. Standiford. 2017. IL-36 receptor deletion attenuates lung injury and decreases mortality in murine influenza pneumonia. *Mucosal Immunol.* 10: 1043–1055.
19. Segueni, N., S. Vigne, G. Palmer, M. L. Bourigault, M. L. Olleros, D. Vesin, I. Garcia, B. Ryffel, V. F. Quesniaux, and C. Gabay. 2015. Limited contribution of IL-36 versus IL-1 and TNF pathways in host response to mycobacterial infection. *PLoS One* 10: e0126058.
20. Kovach, M. A., B. Singer, G. Martinez-Colon, M. W. Newstead, X. Zeng, P. Mancuso, T. A. Moore, S. L. Kunkel, M. Peters-Golden, B. B. Moore, and T. J. Standiford. 2017. IL-36 γ is a crucial proximal component of protective type-1-mediated lung mucosal immunity in Gram-positive and -negative bacterial pneumonia. *Mucosal Immunol.* 10: 1320–1334.
21. Boutet, M. A., G. Bart, M. Penhoat, J. Amiaud, B. Brulin, C. Charrier, F. Morel, J. C. Lecron, M. Rolli-Derkinderen, A. Bourreille, et al. 2016. Distinct expression of interleukin (IL)-36 α , β and γ , their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease. *Clin. Exp. Immunol.* 184: 159–173.
22. Kanda, T., A. Nishida, K. Takahashi, K. Hidaka, H. Imaeda, O. Inatomi, S. Bamba, M. Sugimoto, and A. Andoh. 2015. Interleukin(IL)-36 α and IL-36 γ induce proinflammatory mediators from human colonic subepithelial myofibroblasts. *Front. Med. (Lausanne)* 2: 69.
23. Towne, J. E., B. R. Renshaw, J. Douangpanya, B. P. Lipsky, M. Shen, C. A. Gabel, and J. E. Sims. 2011. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36 α , IL-36 β , and IL-36 γ) or antagonist (IL-36Ra) activity. *J. Biol. Chem.* 286: 42594–42602.
24. Xu, F., S. Lin, X. Yan, C. Wang, H. Tu, Y. Yin, and J. Cao. 2018. Interleukin 38 protects against lethal sepsis. *J. Infect. Dis.* 218: 1175–1184.
25. Ngo, V. L., H. Abo, E. Maxim, A. Harusato, D. Geem, O. Medina-Contreras, D. Merlin, A. T. Gewirtz, A. Nusrat, and T. L. Denning. 2018. A cytokine network involving IL-36 γ , IL-23, and IL-22 promotes antimicrobial defense and recovery from intestinal barrier damage. *Proc. Natl. Acad. Sci. USA* 115: E5076–E5085.
26. Gao, N., R. Me, C. Dai, B. Seyoum, and F. X. Yu. 2018. Opposing effects of IL-1Ra and IL-36Ra on innate immune response to *Pseudomonas aeruginosa* infection in C57BL/6 mouse corneas. *J. Immunol.* 201: 688–699.
27. Heath, J. E., G. M. Scholz, P. D. Veith, and E. C. Reynolds. 2019. IL-36 γ regulates mediators of tissue homeostasis in epithelial cells. *Cytokine* 119: 24–31.
28. Blumberg, H., H. Dinh, E. S. Trueblood, J. Pretorius, D. Kugler, N. Weng, S. T. Kanaly, J. E. Towne, C. R. Willis, M. K. Kuechle, et al. 2007. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. *J. Exp. Med.* 204: 2603–2614.
29. Kovach, M. A., B. H. Singer, M. W. Newstead, X. Zeng, T. A. Moore, E. S. White, S. L. Kunkel, M. Peters-Golden, and T. J. Standiford. 2016. IL-36 γ is secreted in microparticles and exosomes by lung macrophages in response to bacteria and bacterial components. *J. Leukoc. Biol.* 100: 413–421.
30. Wu, T. G., K. R. Wilhelmus, and B. M. Mitchell. 2003. Experimental keratomycosis in a mouse model. *Invest. Ophthalmol. Vis. Sci.* 44: 210–216.
31. Williams, R. N., C. A. Paterson, K. E. Eakins, and P. Bhattacharjee. 1982-1983. Quantification of ocular inflammation: evaluation of polymorphonuclear leucocyte infiltration by measuring myeloperoxidase activity. *Curr. Eye Res.* 2: 465–470.
32. Ross, B. X., N. Gao, X. Cui, T. J. Standiford, J. Xu, and F. X. Yu. 2017. IL-24 promotes *Pseudomonas aeruginosa* keratitis in C57BL/6 mouse corneas. *J. Immunol.* 198: 3536–3547.
33. Gao, N., G. Sang Yoon, X. Liu, X. Mi, W. Chen, T. J. Standiford, and F. S. Yu. 2013. Genome-wide transcriptional analysis of differentially expressed genes in flagellin-pretreated mouse corneal epithelial cells in response to *Pseudomonas aeruginosa*: involvement of S100A8/A9. *Mucosal Immunol.* 6: 993–1005.
34. Fatkhullina, A. R., I. O. Peshkova, A. Dzutsev, T. Aghayev, J. A. McCulloch, V. Thovarai, J. H. Badger, R. Vats, P. Sundh, H. Y. Tang, et al. 2018. An interleukin-23-interleukin-22 axis regulates intestinal microbial homeostasis to protect from diet-induced atherosclerosis. *Immunity* 49: 943–957.e9.
35. Vigne, S., G. Palmer, C. Lamacchia, P. Martin, D. Talabot-Ayer, E. Rodriguez, F. Ronchi, F. Fallusto, H. Dinh, J. E. Sims, and C. Gabay. 2011. IL-36R ligands are potent regulators of dendritic and T cells. *Blood* 118: 5813–5823.
36. Russell, S. E., R. M. Horan, A. M. Stefanska, A. Carey, G. Leon, M. Aguilera, D. Statovci, T. Moran, P. G. Fallon, F. Shanahan, et al. 2016. IL-36 α expression is elevated in ulcerative colitis and promotes colonic inflammation. *Mucosal Immunol.* 9: 1193–1204.
37. Nanjo, Y., M. W. Newstead, T. Aoyagi, X. Zeng, K. Takahashi, F. S. Yu, K. Tateda, and T. J. Standiford. 2018. Overlapping roles for interleukin-36 cytokines in protective host defense against murine *Legionella pneumophila* pneumonia. *Infect. Immun.* 87: e00583-18.
38. Ciccia, F., A. Accardo-Palumbo, R. Alessandro, C. Alessandri, R. Priori, G. Guggino, S. Raimondo, F. Carubbi, G. Valesini, R. Giacomelli, et al. 2015. Interleukin-36 α axis is modulated in patients with primary Sjögren's syndrome. *Clin. Exp. Immunol.* 181: 230–238.
39. Gao, N., A. Kumar, and F. S. Yu. 2015. Matrix metalloproteinase-13 as a target for suppressing corneal ulceration caused by *Pseudomonas aeruginosa* infection. *J. Infect. Dis.* 212: 116–127.
40. Clark, H. L., A. Jhingran, Y. Sun, C. Vareechon, S. de Jesus Carrion, E. P. Skaar, W. J. Chazin, J. A. Calera, T. M. Hohl, and E. Pearlman. 2016. Zinc and manganese chelation by neutrophil S100A8/A9 (calprotectin) limits extracellular *Aspergillus fumigatus* hyphal growth and corneal infection. *J. Immunol.* 196: 336–344.
41. Damo, S. M., T. E. Kehl-Fie, N. Sugitani, M. E. Holt, S. Rathi, W. J. Murphy, Y. Zhang, C. Betz, L. Hench, G. Fritz, et al. 2013. Molecular basis for manganese sequestration by calprotectin and roles in the innate immune response to invading bacterial pathogens. *Proc. Natl. Acad. Sci. USA* 110: 3841–3846.
42. Cassat, J. E., and E. P. Skaar. 2013. Iron in infection and immunity. *Cell Host Microbe* 13: 509–519.
43. Chan, Y. R., J. S. Liu, D. A. Pociask, M. Zheng, T. A. Mietzner, T. Berger, T. W. Mak, M. C. Clifton, R. K. Strong, P. Ray, and J. K. Kolls. 2009. Lipocalin 2 is required for pulmonary host defense against *Klebsiella* infection. *J. Immunol.* 182: 4947–4956.
44. Cramer, E. P., S. L. Dahl, B. Rozell, K. J. Knudsen, K. Thomsen, C. Moser, J. B. Cowland, and N. Borregaard. 2017. Lipocalin-2 from both myeloid cells and the epithelium combats *Klebsiella pneumoniae* lung infection in mice. *Blood* 129: 2813–2817.
45. Liu, X., N. Gao, C. Dong, L. Zhou, Q. S. Mi, T. J. Standiford, and F. S. Yu. 2014. Flagellin-induced expression of CXCL10 mediates direct fungal killing and recruitment of NK cells to the cornea in response to *Candida albicans* infection. *Eur. J. Immunol.* 44: 2667–2679.
46. Kumar, A., N. Gao, T. J. Standiford, R. L. Gallo, and F. S. Yu. 2010. Topical flagellin protects the injured corneas from *Pseudomonas aeruginosa* infection. *Microbes Infect.* 12: 978–989.
47. D'Elios, M. M., M. Benagiano, C. Della Bella, and A. Amedei. 2011. T-cell response to bacterial agents. *J. Infect. Dev. Ctries.* 5: 640–645.
48. Kwon, B., and L. D. Hazlett. 1997. Association of CD4+ T cell-dependent keratitis with genetic susceptibility to *Pseudomonas aeruginosa* ocular infection. *J. Immunol.* 159: 6283–6290.
49. Hazlett, L. D., X. Huang, S. A. McClellan, and R. P. Barrett. 2003. Further studies on the role of IL-12 in *Pseudomonas aeruginosa* corneal infection. *Eye (Lond.)* 17: 863–871.
50. Suryawanshi, A., Z. Cao, T. Thitiprasert, T. S. Zaidi, and N. Panjwani. 2013. Galectin-1-mediated suppression of *Pseudomonas aeruginosa*-induced corneal immunopathology. *J. Immunol.* 190: 6397–6409.
51. Pociask, D. A., E. V. Scheller, S. Mandalapu, K. J. McHugh, R. I. Enelow, C. L. Fattman, J. K. Kolls, and J. F. Alcorn. 2013. IL-22 is essential for lung epithelial repair following influenza infection. *Am. J. Pathol.* 182: 1286–1296.
52. Wolk, K., S. Kunz, E. Witte, M. Friedrich, K. Asadullah, and R. Sabat. 2004. IL-22 increases the innate immunity of tissues. *Immunity* 21: 241–254.
53. Eidenschen, C., S. Rutz, O. Liesenfeld, and W. Ouyang. 2014. Role of IL-22 in microbial host defense. *Curr. Top. Microbiol. Immunol.* 380: 213–236.
54. Sonnenberg, G. F., L. A. Fouser, and D. Artis. 2011. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. *Nat. Immunol.* 12: 383–390.
55. Foster, A. M., J. Baliwag, C. S. Chen, A. M. Guzman, S. W. Stoll, J. E. Gudjonsson, N. L. Ward, and A. Johnston. 2014. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. *J. Immunol.* 192: 6053–6061.
56. Segura, E., J. Valladeau-Guilemond, M. H. Donnadieu, X. Sastre-Garau, V. Soumelis, and S. Amigorena. 2012. Characterization of resident and migratory dendritic cells in human lymph nodes. *J. Exp. Med.* 209: 653–660.